Roche Exorcizes Torcetrapib’s Ghost: CETP Candidate Starts Phase III
This article was originally published in Pharmaceutical Approvals Monthly
If those who do not learn from the past are condemned to repeat it, then Roche’s extensive study of Pfizer’s torcetrapib is the Swiss firm’s attempt to avoid a repeat of the first cholesterol ester transfer protein inhibitor’s performance.
You may also be interested in...
Experts see various reasons why Roche’s HDL-raising drug may have failed to demonstrate benefit in the dal-OUTCOMES study, including insufficient potency resulting from only partial CETP inhibition. Final word on the class’ fate likely will not be written until outcomes studies by Merck and Lilly report out in several years.
European Society of Cardiology Congress abstract for small study suggests Roche's dalcetrapib is safe and works on plaque burden.
CHICAGO – Merck showed dramatic HDL and LDL cholesterol effects and no safety concerns in the Phase III DEFINE study of anacetrapib, but it is still planning to wait to submit the cholesteryl ester transfer protein (CETP) inhibitor until the conclusion of a major outcomes trial.